Barbara Boughton
July 19, 2018
Dive
Brief:
- Food and Drug Administration
Commissioner Scott Gottlieb on Tuesday announced a new effort to
foster consumer access to medicine by making a broader selection of drug
products available without a prescription.
- In a draft guidance, the FDA noted
that changing some prescription drugs to over-the-counter products would
require input from manufacturers to ensure safety and that consumers are
well-informed about them.
- It’s anticipated that drug
companies would have to develop additional informative labeling on drug
packages, and consumers might have to demonstrate that they are buying an
appropriate drug — perhaps through digital apps.
Dive
Insight:
The
announcement is the latest in the FDA’s bid to bring down health costs, an
effort that so far has included timelier review of generic drug applications.
Gottlieb announced in May that the FDA had approved a record number of generic
drugs in 2017, providing full or tentative approvals to 1,000 generic drugs.
Changing
some prescription drugs for chronic conditions to over-the-counter products
would save the healthcare system significant money, and promote easier access
to these drugs for consumers, Gottlieb said in a statement.
"We’re
very mindful of the time and financial cost to patients and the health care
system to fill a prescription medicine — particularly one taken repeatedly for
chronic conditions," he added. "Our hope is that the steps we’re
taking to advance this new more modern framework will contribute to lower costs
for our health care system overall — and provide greater efficiency and
empowerment for consumers by increasing the availability of certain products
that would otherwise be available only by prescription," Gottlieb
said.
Gottlieb
cautioned, however, that any drug that became available without a prescription
would need to meet standards for safety, and consumers would need information
to help them self-select their medications. One of the ways that consumers
could accurately choose medicines would be to pose a series of questions via a
technology app — ensuring that the drug is appropriate for the patient’s health
condition. The designers of such innovative digital approaches, however, would
have to perform studies to demonstrate that the tool would enable consumers to
safely use a drug without a prescription.
All
drugs changed to over-the-counter products would still need to meet the FDA's
"evidentiary standard" for nonprescription drugs, Gottlieb said.
As the agency moves to approve more prescription drugs for over-the-counter
sale, it will also be ensuring safety and effectiveness through robust
scientific review of data on these medications.
Some
examples Gottlieb gave of drugs that could change to over-the-counter products
— with additional labeling and education of consumers — would be
cholesterol-lowering medications and naloxone, a medicine used to rapidly
reverse opioid overdose.
Gottlieb
acknowledged that the drug guidance issued Tuesday was just a first step. The effort
would also require the FDA to closely collaborate and coordinate with industry
and other healthcare stakeholders to strike the right balance between improving
access and safeguarding public health, he said.
No comments:
Post a Comment